Lowenstein Sandler Welcomes Mary E. Storella, Former VP-Corporate Transactions at Celgene, as Head of Life Sciences Transactions
Lowenstein Sandler has announced that Mary E. Storella has joined the firm’s Life Sciences group as the group’s Vice Chair and head of Life Sciences Transactions. Mary will focus on mergers and acquisitions, early and late stage collaborations, licenses, options, co-development and co-commercialization collaborations, clinical collaborations, and diagnostic collaborations in the pharmaceutical, biotech, and other industries.
Storella has over 15 years of experience supporting strategic life sciences transactions, most recently as Vice President and Senior Counsel, Corporate Transactions, at Celgene Corporation. There she led and supported a broad spectrum of deals, including the company’s $67 billion sale to Bristol Myers Squibb, Celgene’s $13.4 billion divestiture of Otezla to Amgen, the company’s $9 billion acquisition of Juno Therapeutics, and its $300 million acquisition of Delinia, Inc.
Prior to Celgene, Storella worked as both an attorney and Executive Director of Business Development at Merck & Co. Inc., where she headed a transaction team on all aspects of licensing, partnerships, and acquisition opportunities. Representative transactions at Merck include Merck’s $14.2 billion divestiture of its consumer care business to Bayer, its $10 billion acquisition of Cubist Pharmaceuticals, and the licensing of Phase III oncology product and collaboration with Endocyte.
Storella earned her J.D from Pace University Law School and her B.A. from University of North Carolina at Chapel Hill.
